تحميل...
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors
Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refract...
محفوظ في:
| الحاوية / القاعدة: | Cancer Biol Ther |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Taylor & Francis
2014
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4623403/ https://ncbi.nlm.nih.gov/pubmed/25485960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.986967 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|